Nektar Therapeutics (XTER:ITH0) 1-Year Sharpe Ratio: N/A (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:ITH0 Nektar Therapeutics XTER:ITH0
35 GF Score
Price €64.28
GF Value €4.99
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Nektar Therapeutics 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-23), Nektar Therapeutics's 1-Year Sharpe Ratio is Not available.

Nektar Therapeutics  (XTER:ITH0) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Nektar Therapeutics 1-Year Sharpe Ratio Related Terms

XTER:ITH0 vs : 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Nektar Therapeutics's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nektar Therapeutics 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's 1-Year Sharpe Ratio falls into.


XTER:ITH0
35GF Score
Nektar Therapeutics XTER:ITH0
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Is Nektar Therapeutics (XTER:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €64.28 is trading 1188.2% above its estimated GF Value™ of €4.99. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for XTER:ITH0:

  • 1-Year Sharpe Ratio: N/A
  • GF Value™: €4.99 vs. price of €64.28 (1188.2% above fair value)
  • GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the XTER:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Comparable Companies
Other Exchanges NKTR:USA0UNL:UK
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
35GF Score

Get the complete analysis for XTER:ITH0

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.28
Price
€4.99
GF Value